EGF antagonist (Medical Research Council)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameEGF antagonist (Medical Research Council)
Drug Alias Nameanticancer therapeutic (Medical Research Council)argos
ClassificationBiologics > Protein drugs > Recombinant polypeptideNatural product/Extract
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMedical Research Council
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedical Research Council
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A